BELLUS Health Inc. (TSE:BLU – Get Rating)’s stock price crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$13.23 and traded as high as C$19.45. BELLUS Health shares last traded at C$19.39, with a volume of 6,524 shares changing hands.
Wall Street Analyst Weigh In
Separately, Lifesci Capital downgraded shares of BELLUS Health from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 18th.
BELLUS Health Stock Down 0.2 %
The firm’s 50 day simple moving average is C$13.23 and its 200 day simple moving average is C$12.18. The company has a market cap of C$2.46 billion, a price-to-earnings ratio of -22.03 and a beta of -0.49. The company has a quick ratio of 16.40, a current ratio of 22.42 and a debt-to-equity ratio of 0.33.
BELLUS Health Company Profile
BELLUS Health Inc, a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.
- Occidental Petroleum: Will Buffet Buy More?
- 5 Best Healthcare Sector ETFs
- Electronic Arts Has Game But Can Share Price Move Higher?
- Wendy’s May Have Just Become A Value Play
- Rivian Leads EV Startups But Will The Stock Move Higher?
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.